TMCnet News
Noxopharm Announces Appointment of Chief Commercial Officer
SYDNEY, Australia, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Noxopharm (ASX:NOX) is pleased to announce that it has appointed Mr Alexander Hunter as its Chief Commercial Officer. Mr Hunter has 15 years of experience in corporate finance, capital raising, mergers and acquisitions and growth company strategy in Australian and U.S. operating environments. He was previously Chief Financial Officer of an ASX listed energy company where he was part of an executive team that successfully transformed the US based business to grow annual revenue from $0 to over $200m, complete asset acquisitions of over $250m and raise over $300m in equity and debt. He holds an MBA from University of Southern California Marshall School of Business, a Bachelor of Engineering, and postgraduate qualifications in corporate finance and business law. Previously he held senior roles at ASX listed growth company Drillsearch Energy and corporate finance advisory firm RFC Ambrian. Prior to his career in corporate finance Mr Hunter worked for 10 years in project management of engineering and construction projects and corporate change management roles. Mr Hunter’s strong corporate finance, commercial and operational skills will add important management strength to the Noxopharm executive team during a time of critical transformation for the Company as it embarks on its next phase of growth. < align="justify">Dr Graham Kelly, Noxopharm CEO and Executive Chairman, said, “The Company’s upcoming period of corporate and business growth stemming from its proposed dual listing in 2020, and emerging opportunities from the development of Veyonda® and its planned expanded clinical program, require strengthening of the executive team with a seasoned corporate finance and business executive.Alex brings this strength to the Noxopharm team and we are delighted that he is joining the Company at this exciting time. He will draw on his listed company financial and operating experience in Australia and the U.S. to help Noxopharm drive its growth objectives.” About Noxopharm
Forward Looking Statements |